Abstracts tagged "Biologicals"

Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…
Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Fahad Ahmed¹, Syed M. Rahman², Sarah Trent³, Lap Pham³, Nashwah Memon⁴, Hannah Chung³ and Adel Haque⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³PA Dermatology Partners, Philadelphia, PA, ⁴Lake Erie College of Osteopathic Medicine, Bradenton, FL, ⁵Jefferson Health - Northeast, Philadelphia, PA
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…
Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Franziska Neinert¹, Imke Redeker², Styliani Tsiami¹, David Kiefer¹, Barbara Guminski¹, Xenofon Baraliakos³, Juergen Braun¹ and Uta Kiltz⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Ruhr Universität Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…
Abstract Number: 1566 • ACR Convergence 2023
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Christine Xu¹, Ying Liu¹, Jennifer Sloane², Remco Diab³, Hubert van Hoogstraten¹, Hisham Abdallah⁴, Sreeraj Macha¹ and Bhaskar Dasgupta⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Cambridge, MA, ³Sanofi, Rotkreuz, Switzerland, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Richard Eastell¹, Bente Langdahl², Yoon-Sok Chung³, Rafal Plebanski⁴, Edward Czerwinski⁵, Eva Dokoupilova⁶, Jerzy Supronik⁷, Jan Rosa⁸, Anna Rowińska-Osuch⁹, Ki-Hyun Baek¹⁰, Audrone Urboniene¹¹, Sohui Ahn¹², Younghee Rho¹² and Jisuk Ban¹², ¹University of Sheffield, Sheffield, United Kingdom, ²Aarhus University Hospital, Aarhus, Denmark, ³Ajou University Hospital, Suwon, South Korea, ⁴Klinika Zdrowej Kosci, Łódź, Poland, ⁵Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, ⁶Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁷OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ⁸Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, ⁹ETG Warszawa, Warszawa, Poland, ¹⁰Yeouido ST. Mary's Hospital, Seoul, South Korea, ¹¹JSC Saules seimos medicinos centras, Kaunas, Lithuania, ¹²Samsung Bioepis, Incheon, South Korea
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
Abstract Number: 2218 • ACR Convergence 2023
Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
John Koussiouris¹, Nikita Looby¹, Max Kotlyar², Vathany Kulasingam³, Igor Jurisica⁴, Ashish J Mathew⁵, Proton Rahman⁶ and Vinod Chandran⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Christian Medical College, Vellore, India, ⁶Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The use of biologic disease-modifying anti-rheumatic drugs (bDMARDS) is the current standard of care for severe diseases like psoriatic arthritis (PsA) which affects approximately…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 2545 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
Atul Deodhar¹, Jerzy Supronik², Alan Kivitz³, Guillermo Valenzuela⁴, Karen Kapur⁵, Susanne Rohrer⁶, Eva Dokoupilova⁷, Hanno Richards⁶ and Karel Pavelka⁸, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0505 • ACR Convergence 2023
Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
Shashank Cheemalavagu¹, Yuxuan Jin² and M. Elaine Husni³, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Achieving minimal disease activity (MDA) is an important treatment goal in psoriatic arthritis (PsA), as it leads to improved clinical outcomes and quality of…
Abstract Number: 0597 • ACR Convergence 2023
Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Withrop⁷, Ihor Hupka⁸, Micki Hultquist⁹, Raj Tummala⁹, Gabriel Abreu¹⁰, Catharina Lindholm¹⁰ and Hussein Al-Mossawi¹¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁸BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland, ⁹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹⁰BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a systemic autoimmune disease requiring long-term treatment. In this placebo-controlled phase 3 TULIP long-term extension (LTE) study,1 the impact of anifrolumab in…
Abstract Number: 0988 • ACR Convergence 2023
Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Vijaya Rivera Terán¹, David Vega Morales², Miguel Angel Saavedra Salinas³, Daniel Xavier Xibillé Friedman⁴, Iris Colunga⁵, Sandra Carrillo Vazquez⁶, Dafhne Miranda Hernández⁷, Sergio Durán Barragán⁸, Erick Adrián Zamora Tehozol⁹, Angel Alejandro Castillo Ortiz¹⁰, Sandra Sicsik Ayala¹¹, Fedra Irazoque Palazuelos⁶, Julio César Casasola Vargas¹², Angelica Peña¹³, Omar Eloy Muñoz Monroy¹⁴, Azucena Ramos Sánchez², Luis Valdés Corona¹⁵, Javier Merayo-Chalico¹⁶, Estefania Torres Valdez¹³, Aleni Paz Viscarra¹⁵ and Deshiré Alpízar Rodríguez¹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³IMSS, Mexico City, Mexico, ⁴Práctica Privada, Cuernavaca, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico, ⁶Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Consulta Privada, Guadalajara, Mexico, ⁹Centro Médico Pensiones, Mérida, Mexico, ¹⁰Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, ¹¹Instituto Mexicano del Seguro Social, Torreón, Mexico, ¹²Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Hospital Central Militar, Mexico City, Mexico, ¹⁵Práctica Privada, Mexico City, Mexico, ¹⁶Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico
Background/Purpose: The approach to elderly patients (≥60 years) with rheumatic diseases offers certain difficulties and uncertainties. Older adults are a particularly vulnerable group who often…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 1399 • ACR Convergence 2023
Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data
Ansaam Daoud¹, Sadeer Al-Kindi² and Marina Nighat Magrey³, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH
Background/Purpose: Ankylosing Spondylitis (AS) is associated with an increased risk of cardiovascular disease, partly due to systemic inflammation, and an increased risk of vascular mortality.…
Abstract Number: 1572 • ACR Convergence 2023
Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis
Tsuyoshi Shirai¹, Hiroko Sato¹, Tomonori Ishii² and Hiroshi Fujii¹, ¹Tohoku University, Sendai, Japan, ²Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Takayasu arteritis (TAK) is a type of large-vessel vasculitis that predominantly affects young females. The relapse is frequent, accounting for 60% of cases, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].